The BD&L community is dedicated to dealmaking in the life sciences industry, bringing together cross-functional experts from pharma, biotech and VCs to share best practices in due diligence, capital raising and M&A, licensing, and strategic alliance transactions.
With general BD&L sessions and two tracks dedicated to asset-based and platform/non-molecule-driven deals, attendees can customize their learning experience and gain insights that will help them unlock the potential of a deal and drive a company’s competitive position in the marketplace.
Key topics covered in the BD&L track:
Deal Drivers and Investment Priorities for Big Pharma and VCs
Operating Models for Search and Evaluation to Advance Innovation
IP Due Diligence Issues that can Derail a Deal
Dealmaking Trends and Insights for New Modalities and Technologies
Alternative Deal Constructs and Creative Financing
Negotiating and Evaluating Platform Deals
